SEVİN, G. Et Al. 2018. A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor. Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) .

SEVİN, G., Alançay, E., Yılmaz, S., ALPTÜZÜN, V., & YETİK ANACAK, G. Y., (2018). A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor . Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)

SEVİN, GÜLNUR Et Al. "A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor," Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig), 2018

SEVİN, GÜLNUR Et Al. "A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor." Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) , 2018

SEVİN, G. Et Al. (2018) . "A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor." Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) .

@conferencepaper{conferencepaper, author={GÜLNUR SEVİN Et Al. }, title={A new multitargeted drug candidate in Alzheimer disease: 1,4-dihydropyridine-benzylidenhydrazon derived AChE inhibitor}, congress name={Second WG Meeting COST ACTION CA15135, Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)}, city={}, country={}, year={2018}}